Literature DB >> 16048936

Production and characterization of stable amphotericin-resistant amastigotes and promastigotes of Leishmania mexicana.

Hamdan I Al-Mohammed1, Michael L Chance, Paul A Bates.   

Abstract

The sensitivities of Leishmania mexicana amastigote and promastigote forms to amphotericin B were investigated in vitro and found to be strongly influenced by the culture media used. When differences in culture media were minimized, there was no significant difference in the 50% inhibitory concentration values between the two life cycle stages. Stable amphotericin B-resistant amastigote and promastigote lines were produced by the application of increasing drug pressure to long-term cultures. Lines capable of growth in concentrations of amphotericin B lethal to normal parasites were produced. Compared to normal parasites, these amphotericin-resistant lines showed marked differences in membrane sterol compositions, with very high levels of 4,14,dimethyl-cholesta-8,24-dienol and other methyl sterols. They also showed a consistent morphological feature, the presence of multilamellar membrane-like material in the flagellar pocket, revealed by transmission electron microscopy. Amphotericin-resistant parasites were capable of infecting BALB/c mice, but the resulting lesion growth was slower than that after infection with normal parasites. However, unlike normal parasites, the amphotericin-resistant parasites were unaffected by experimental chemotherapy with amphotericin B. These results show that amphotericin B resistance could arise as a result of increased clinical use of amphotericin B therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16048936      PMCID: PMC1196255          DOI: 10.1128/AAC.49.8.3274-3280.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

Review 1.  Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.

Authors:  M A Ghannoum; L B Rice
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

2.  Drug resistance in Indian visceral leishmaniasis.

Authors:  S Sundar
Journal:  Trop Med Int Health       Date:  2001-11       Impact factor: 2.622

3.  Gene amplification in amphotericin B-resistant Leishmania tarentolae.

Authors:  A K Singh; B Papadopoulou; M Ouellette
Journal:  Exp Parasitol       Date:  2001-11       Impact factor: 2.011

4.  Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases.

Authors:  C P Thakur; R K Singh; S M Hassan; R Kumar; S Narain; A Kumar
Journal:  Trans R Soc Trop Med Hyg       Date:  1999 May-Jun       Impact factor: 2.184

5.  Ultrastructural and biochemical alterations induced by 22,26-azasterol, a delta(24(25))-sterol methyltransferase inhibitor, on promastigote and amastigote forms of Leishmania amazonensis.

Authors:  Juliany C F Rodrigues; Márcia Attias; Carlos Rodriguez; Julio A Urbina; Wanderley de Souza
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

6.  Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters.

Authors:  Ajay K Agrawal; A Agrawal; A Pal; P Y Guru; C M Gupta
Journal:  J Drug Target       Date:  2002-02       Impact factor: 5.121

Review 7.  Chemotherapy of leishmaniasis.

Authors:  Simon L Croft; Vanessa Yardley
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

8.  Design and antileishmanial activity of amphotericin B-loaded stable ionic amphiphile biovector formulations.

Authors:  P M Loiseau; L Imbertie; C Bories; D Betbeder; I De Miguel
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

9.  A policy for leishmaniasis with respect to the prevention and control of drug resistance.

Authors:  A Bryceson
Journal:  Trop Med Int Health       Date:  2001-11       Impact factor: 2.622

Review 10.  Leishmaniasis: recognition and management with a focus on the immunocompromised patient.

Authors:  Christine M Choi; Ethan A Lerner
Journal:  Am J Clin Dermatol       Date:  2002       Impact factor: 7.403

View more
  17 in total

1.  Selection and phenotype characterization of potassium antimony tartrate-resistant populations of four New World Leishmania species.

Authors:  Daniel B Liarte; Silvane M F Murta
Journal:  Parasitol Res       Date:  2010-04-07       Impact factor: 2.289

2.  Anti-leishmanial effects of purified compounds from aerial parts of Baccharis uncinella C. DC. (Asteraceae).

Authors:  Luiz Felipe D Passero; Alexis Bonfim-Melo; Carlos Eduardo P Corbett; Márcia D Laurenti; Marcos H Toyama; Daniela O de Toyama; Paulete Romoff; Oriana A Fávero; Simone S dos Grecco; Cynthia A Zalewsky; João Henrique G Lago
Journal:  Parasitol Res       Date:  2010-10-01       Impact factor: 2.289

3.  Amphotericin B resistance in Leishmania mexicana: Alterations to sterol metabolism and oxidative stress response.

Authors:  Edubiel A Alpizar-Sosa; Nur Raihana Binti Ithnin; Wenbin Wei; Andrew W Pountain; Stefan K Weidt; Anne M Donachie; Ryan Ritchie; Emily A Dickie; Richard J S Burchmore; Paul W Denny; Michael P Barrett
Journal:  PLoS Negl Trop Dis       Date:  2022-09-28

4.  Effectiveness and Safety of Amphotericin B Deoxycholate, Amphotericin B Colloidal Dispersion, and Liposomal Amphotericin B as Third-Line Treatments for Cutaneous and Mucocutaneous Leishmaniasis: A Retrospective Study.

Authors:  María Claudia Rodríguez Galvis; Jairo Enrique Pérez Franco; Mirian Yolanda Casas Vargas; María Fernanda Ordoñez Rubiano
Journal:  Am J Trop Med Hyg       Date:  2020-02       Impact factor: 2.345

5.  Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis.

Authors:  Pouran Layegh; Omid Rajabi; Mahmoud Reza Jafari; Parisa Emamgholi Tabar Malekshah; Toktam Moghiman; Hami Ashraf; Roshanak Salari
Journal:  J Parasitol Res       Date:  2011-11-24

6.  Comparative Fitness of a Parent Leishmania donovani Clinical Isolate and Its Experimentally Derived Paromomycin-Resistant Strain.

Authors:  Sarah Hendrickx; Annelies Leemans; Annelies Mondelaers; Suman Rijal; Basudha Khanal; Jean-Claude Dujardin; Peter Delputte; Paul Cos; Louis Maes
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

Review 7.  Comparative analysis of the omics technologies used to study antimonial, amphotericin B, and pentamidine resistance in leishmania.

Authors:  Gagandeep Kaur; Bhawana Rajput
Journal:  J Parasitol Res       Date:  2014-05-12

8.  Fitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania major.

Authors:  Kimbra G Turner; Paola Vacchina; Maricela Robles-Murguia; Mariha Wadsworth; Mary Ann McDowell; Miguel A Morales
Journal:  PLoS Negl Trop Dis       Date:  2015-07-31

9.  Efficacy of intralesional amphotericin B for the treatment of cutaneous leishmaniasis.

Authors:  Vahid Mashayekhi Goyonlo; Elham Vosoughi; Bita Kiafar; Yalda Nahidi; Akram Momenzadeh; Ahmad Reza Taheri
Journal:  Indian J Dermatol       Date:  2014-11       Impact factor: 1.494

Review 10.  Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.

Authors:  Alicia Ponte-Sucre; Francisco Gamarro; Jean-Claude Dujardin; Michael P Barrett; Rogelio López-Vélez; Raquel García-Hernández; Andrew W Pountain; Roy Mwenechanya; Barbara Papadopoulou
Journal:  PLoS Negl Trop Dis       Date:  2017-12-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.